ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 33.54M USD | Liabilities, Current |
| Cash and equivalents | 191.48M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 1.81M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $33.54M | $191.48M | (m) | $1.81M | (m) | (m) |
| 2026-03-31 | (m) | $34.37M | $211.38M | (m) | $1.34M | (m) | (m) |
| 2025-12-31 | (m) | $36.38M | $230.91M | (m) | $5.56M | (m) | (m) |
| 2025-09-30 | (m) | $31.70M | $180.36M | (m) | $7.95M | (m) | (m) |
| 2025-06-30 | (m) | $46.52M | $196.47M | (m) | $17.20M | (m) | (m) |
| 2025-03-31 | (m) | $49.41M | $216.95M | (m) | $14.57M | (m) | (m) |
| 2024-12-31 | (m) | $65.49M | $237.03M | (m) | $3.97M | (m) | (m) |
| 2024-09-30 | (m) | $69.46M | $237.18M | (m) | $30.20M | (m) | (m) |
| 2024-06-30 | (m) | $91.72M | $260.33M | (m) | $24.09M | (m) | (m) |
| 2024-03-31 | (m) | $115.43M | $288.40M | (m) | $27.06M | (m) | (m) |
| 2023-12-31 | (m) | $81.99M | $292.00M | (m) | $32.06M | (m) | (m) |
| 2023-09-30 | (m) | $87.68M | $311.92M | (m) | $38.22M | (m) | (m) |
| 2023-06-30 | (m) | $90.34M | $323.47M | (m) | $2.80M | (m) | (m) |
| 2023-03-31 | (m) | $90.13M | $327.94M | (m) | $92.48M | (m) | (m) |
| 2022-12-31 | (m) | $126.98M | $391.88M | (m) | $2.76M | (m) | (m) |
| 2022-09-30 | (m) | $75.85M | $237.68M | (m) | $2.04M | (m) | (m) |
| 2022-06-30 | (m) | $92.74M | $283.49M | (m) | $2.25M | (m) | (m) |
| 2022-03-31 | (m) | $107.31M | $319.68M | (m) | $3.69M | (m) | (m) |
| 2021-12-31 | (m) | $99.54M | $370.49M | (m) | $3.37M | (m) | (m) |
| 2021-09-30 | (m) | $118.24M | $413.88M | (m) | $2.02M | (m) | (m) |
| 2021-06-30 | (m) | $70.77M | $433.57M | (m) | $2.16M | (m) | (m) |
| 2021-03-31 | (m) | $53.33M | $466.84M | (m) | $2.01M | (m) | (m) |
| 2020-12-31 | (m) | $49.52M | $462.89M | (m) | $2.13M | (m) | (m) |
| 2020-09-30 | (m) | $28.01M | $307.02M | (m) | $2.45M | (m) | (m) |
| 2020-06-30 | (m) | $23.05M | $136.11M | (m) | $2.83M | (m) | (m) |
| 2020-03-31 | (m) | $21.65M | $59.47M | (m) | $2.35M | (m) | (m) |
| 2019-12-31 | (m) | $21.32M | $71.35M | (m) | $2.18M | (m) | (m) |
| 2019-09-30 | (m) | $21.69M | $74.17M | (m) | $2.63M | (m) | (m) |
| 2019-06-30 | (m) | $16.41M | $55.84M | (m) | $5.82M | (m) | (m) |
| 2019-03-31 | (m) | (m) | $31.22M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $12.58M | $36.71M | (m) | $4.48M | (m) | (m) |
| 2018-09-30 | (m) | (m) | $30.33M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $29.32M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |